LUNG Pulmonx (LUNG) Q3 FY26 earnings call
Pulmonx delivered an inflection quarter, resuming top-line expansion while demonstrating aggressive cost realignment that reduced cash operating expenses by 16% YoY. Management's focused commercial strategy in the U.S. and pipeline progression toward international AeriSeal commercialization support a durable pathway toward cash flow breakeven.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
LUNG operating KPIs by quarter
| KPI | Jun 2026 Q2 FY26 | This call Sep 2026 Q3 FY26 | Change vs prior quarter |
|---|---|---|---|
| New treating centers US | 12we added 12 new US treating centers during the quarter.Source: earnings call transcript | 8We added 8 new US treating centers during the quarter.Source: earnings call transcript | -33.3% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.